In the present study subcutaneous ®brosarcomas were induced by the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) in rats from F1 generation cross breedings of two dierent inbred strains. Comparative genomic hybridization (CGH) analysis, which allows detection of DNA sequence copy changes, was applied to one of the tumors and it was found that there were increased copy numbers of sequences at chromosome 4q12-q21 in this tumor. We have previously determined that the loci for the hepatocyte growth factor (Hgf) and hepatocyte growth factor receptor (Hgfr/Met), a protooncogene, are situated in this particular chromosome region. Using probes for the two genes in FISH (¯uorescence in situ hybridization) and in Southern blots we found that the Hgfr/Met gene was ampli®ed in ®ve of the 19 sarcomas studied, and that the Hgf gene was coampli®ed in two of them. Northern and Western blots and tyrosine phosphorylation analysis showed that the HGF receptor was overexpressed and functional in all ®ve tumors, as well as in two additional tumors. In summary, both ampli®cation and overexpression of the Hgfr/Met gene was found in about 25% of DMBAinduced experimental rat sarcomas, and HGF receptor overexpression alone was seen in two additional tumors. Possibly this re¯ects an involvement in paracrine or autocrine stimulation of growth and invasiveness by HGF. Our ®nding could provide a rodent model system to increased knowledge about causality and therapy, which may be applicable to the sizeable fraction of human musculoskeletal tumors displaying MET overexpression.
Introduction
Since neoplastic disease is a heterogeneous entity characterized by multiple genetic changes, the analysis of human tumors is hampered by the fact that each patient's disease has developed on a unique genetic background interacting with a unique set of environmental factors. Presumably this is the reason why human tumors, even if they are pathologically classi®ed as the same type, often appear as a heterogeneous entity when assesed by available biological methods (Mitelman et al., 1997) . It is expected that a less heterogeneous population of tumors will be obtained if a model organism can be studied. In this case, the in¯uence of diversity in genetic and environmental factors may be minimized by the use of isogenetic animals and controlled experimental conditions.
Polycyclic aromatic hydrocarbons such as 7,12-dimethylbenz(a)anthracene (DMBA) have been used extensively to induce experimental cancers in rodents. These methods have been successful, but have led to the identi®cation of a limited number of mutations that could be of importance for the development of cancers. It has been shown that DMBA-induced skin tumors in mice often exhibit speci®c mutations of the Ha-ras and p53 genes (Quintanilla et al., 1986; Ruggeri et al., 1993) . In contrast, DMBA induced rat mammary tumors infrequently have mutations in these genes (Kito et al., 1996; Zarbl et al., 1985) . Instead, it has recently been shown that DMBA-induced primary rat mammary tumors, like some human mammary tumors, have enhanced activity of the nuclear factor-kappa b/Rel (Sovak et al., 1997) .
A couple of decades ago we were able to show that rat subcutaneous sarcomas induced by DMBA display patterns of chromosome changes that are distinctly dierent from those found in sarcomas induced by Rous sarcoma virus . The fact that this dierence in chromosome pattern could be detected, is in itself a clear indication that these experimental tumors are genetically more homogeneous than most human tumors. Unlike in DMBAinduced cancers, no speci®c gene aberration has been identi®ed in DMBA-induced sarcomas. In the present communication we decided to apply modern molecular techniques to ®nd out if speci®c gene changes with relevance to the carcinogenic process could be detected in a series of newly induced rat DMBA sarcomas. We found that even under these controlled experimental conditions there seemed to be considerable betweentumor variation, as evidenced by a complex pattern of chromosome changes. However, in ®ve out of 19 tumors there was a speci®c genetic aberration; DNA ampli®cation involving the Hgfr/Met oncogene, the gene coding for the receptor for the hepatocyte growth factor (HGF; Matsumoto and Nakamura, 1996) . To our knowledge, this gene has not previously been reported to be ampli®ed in experimental tumors. LB137T  LB130T  LB32T  BL170T  BL150T  LB131T  BL172T  LB135T  BL153T  LB10T  LB140T  LB20T  BL151T  LB142T  LB31T  LB136T  LB133T  LB30  LB132 ++ ± ++ ± (+) +++ ± ± ± ± ± ± (+ MET-amplification in rat DMBA sarcomas K Helou et al
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Cytogenetic analysis and CGH-analysis of the LB32T tumor
The cytogenetic analysis of the 17 cell cultures derived from the tumors showed that about one-third of the tumor lines exhibited sizeable chromosome regions with a stereotype, light staining, usually referred to as HSR (homogeneously staining regions) and indicative of increased copy numbers of chromatin segments (`gene ampli®cation'; Biedler and Spengler, 1976; Levan et al., 1976; Nunberg et al., 1978) . Information about ampli®cation, the location of the HSR regions, and other characteristic cytogenetic aberrations is given in Table 1 . The cells from line LB32T were mainly in the neardiploid range, displaying some consistent chromosomal rearrangements involving RNO4 and RNO6. In the rearranged chromosomes, very clear HSR were seen ( Figure 1a ). The CGH study demonstrated that there was an elevated copy number of the chromosome region RNO4q12-q21 in the LB32T tumor ( Figure 1b) .
Ampli®cation of the genes for HGF and the HGF receptor in rat sarcomas
Since both the Hgf locus and the Hgfr/Met locus map to the RNO4q12-q21 chromosome region (Wallenius et al., 1997) , we wanted to investigate if these genes were involved in gene ampli®cation. Southern blotting of DNA from the LB32T cell line as well as from the LB32T solid tumor tissue showed that there was ampli®cation of both the Hgf gene and the Hgfr/Met gene. When all the rat sarcomas were tested in this way, it was found that another four of them also displayed Hgfr/Met ampli®cation (Figure 2 ; Table 1 ). For any particular tumor the level of Hgfr/Metampli®cation was about the same in the DNA from the solid tumor tissue as in the DNA from the cell cultures. The level of Hgfr/Met ampli®cation in the dierent tumors could be estimated as described, and it was found that the degree of ampli®cation was about 806 in LB137T, 506 in BL150T, 306 in LB32T, 206 in LB133T and 106 in LB 131 (Table 1) .
Rehybridization using the Hgf probe showed that this gene was coampli®ed in two of the tumors (including the LB32T tumor). The tumor lines exhibiting ampli®cation of Hgfr/Met or of Hgfr/ Met+Hgf generally coincided with those exhibiting cytogenetic signs of gene ampli®cation (Table 1 ). In one case (BL150T) the HSR was quite small, forming a small short arm on the (normally telocentric) RNO4 chromosome (see insert in Figure 5 ). There were two cases (sarcomas LB31T and LB136T) in which HSR were seen cytogenetically, but no ampli®cation of Hgfr/ Met and/or Hfg was detected (Table 1) .
Since it is not uncommon that the c-myc is ampli®ed in a variety of tumor types (Schwab et al., 1985) we decided to test whether the Myc gene region might be ampli®ed in any of the DMBA sarcomas. However, there were no signs of Myc ampli®cation in any of the tumors (data not shown).
Overexpression of HGF receptor and HGF in the rat sarcomas
RNA samples from all of the cell lines were tested for overexpression of Hgfr/Met or Hgf. As seen in Figure  3 (upper panel) and Table 1 , there was overexpression of Hgfr/Met in tumors LB137T (very high expression) BL150T, LB133T, LB32T and LB131T, i.e. exactly those that also exhibit Hgfr/Met ampli®cation ( Figure  2 ). The estimated level of overexpression in these C=DNA sample from tumor cell culture; N=DNA sample from normal liver sample. The ®ve tumors (BL150T, LB133T, LB137T, LB131T, LB32T) exhibit dierent levels of Hgfr/Met amplification. Whenever DNA from both solid tumor and the corresponding cell culture are compared, the level of amplification of the Hgfr/Met sequences is approximately the same tumor lines correlated well with the level of DNA ampli®cation. The remaining tumor lines exhibited very low or undetectable levels of Hgfr/Met expression. The presence of the HGF receptor protein was also tested in Western blots using anti-Met antibodies as described. As shown in Figure 4a (upper panel), there were high levels of the HGF receptor protein in tumors LB137T (very high level), BL150T, LB133T, LB32T, LB131T, i.e. those that exhibit Hgfr/Met gene ampli®cation. In addition, HGF receptor overexpression at the protein level was detected in LB130T and LB170T, which exhibited no Hgfr/Met gene amplification. Binding of HGF leads to phosphorylation and activation of the HGF receptor protein. We tested whether the receptors in the tumor cell lines were functional, and found this to be the case as shown in Figure 4 .
We also tried to clarify the involvement of HGF in these tumors. As mentioned above, Hgf was coampli®ed with Hgfr/Met in two of the tumors (LB32T and LB131T) and the phosphorylation of the HGF receptor protein in all of the tumors displaying ampli®cation and HGF receptor expression was suggestive of the presence of active Hgf. Expression of Hgf was studied by Northern analysis of Hgf mRNA ( Figure 3 ) and by the measurement of immunoreactive rat HGF in the culture medium by ELISA (Figure 4 ). In the two tumor lines displaying both Hgfr/Met and Hgf ampli®cation (LB32T and LB131T) there was some HGF mRNA expression, but this was not corroborated by the protein analysis (Table 1 ). In contrast, some of the tumor lines that did not exhibit Hgfr/Met gene ampli®cation displayed evidence of overexpression of HGF by both Northern blot and ELISA (high levels in LB135T, BL172T, BL153T, low but measurable levels in LB20T; Figures 3 and 4b) or by Northern blot only (BL151T, LB140T; Figure 3) . Thus, the phosphorylation of the HGF receptor in the cell cultures may be accounted to other factors than autocrine HGF stimulation (see Discussion).
Subchromosomal localization of the ampli®ed Hgfr/Met sequences to the HSR All of the 17 tumor cell lines available were also tested by FISH with the probes for Hgfr/Met and Hgf. In all intact RNO4 chromosomes present, hybridization to the`native gene sites' on RNO4q12 and RNO4q21, respectively, could be clearly seen. In those lines exhibiting ampli®cation of Hgfr/Met or of Hgfr/ Met+Hgf, numerous signals were also found over the HSR regions ( Figure 5 ). This was true for Hgfr/ Met in those lines exhibiting Hgfr/Met ampli®cation only, whereas both probes gave signals from HSRs in those two sarcomas that exhibited ampli®cation of both genes (LB32T, Figure 5a ,b and LB131T). In most cases the signals were spread out over a quite large region in the metaphase chromosomes and also over a fairly large area in each resting nucleus (Figure 5a,b) , suggesting that the amplicons were quite large. It is reasonable to assume that in these cases numerous genes may be coampli®ed. Furthermore, we noticed in LB32T that all of the resting nuclei displayed ampli®cation of the Hgfr/Met oncogene, whereas only about 10 per cent of them showed signs of Hgf ampli®cation, suggesting that, at least in this tumor, the DNA composition of the amplicons was dierent in dierent cells. The BL150T sarcoma diered from the rest in that the Hgfr/Met signals were always concentrated to a very small HSR situated proximally in RNO4, actually forming a small p arm (Figure 5c ). The signal intensity showed that this small region contained many copies of the Hgfr/Met target gene. A similar picture emerged from the resting nuclei, one or two compact areas of probe signals were seen in each nucleus, which implies that this HSR consisted of the Hgfr/Met gene and not much additional genetic material (Figure 5d ).
Discussion
Sarcomas are derived from mesenchymal tissue, that normally have very low, if any, expression of the Hgfr/ Met gene and few HGF receptors . However, we found in a series of DMBA-induced experimental sarcomas in rats that there was ampli®cation of the Hgfr/Met oncogene in ®ve of the 19 tumors, as well as in the cell cultures derived from them, and that this was accompanied by a distinct overexpression of the HGF receptor messenger RNA as well as of the HGF receptor protein. Two additional tumors showed expression of the HGF receptor protein on Western blots in the absence of Hgfr/Met gene ampli®cation. Furthermore, the HGF receptors from the sarcomas had the capacity to be activated as shown by tyrosine phosphorylation, an activation that normally takes place in response to binding of its ligand, HGF.
It has been shown that the HSR in tumor cells represent gene ampli®cation and are generated in response to selection pressure (Schwab et al., 1985; Stark and Wahl, 1984) . Thus, it can be assumed that the gene ampli®cation observed cytogenetically as HSR in these sarcomas provides the cells with some selective growth advantage. However, the fact that Hgfr/Met and/or Hgf are indeed ampli®ed does not prove that they ar the target of selection. In fact, they may be coampli®ed with some unknown gene, which is located in the same chromosomal region in RNO4 and upon which selection acts. However, there are certain circumstances that suggest that in this particular instance the Hgfr/Met gene is the true target of selection. Firstly, the amplicon in one of the sarcomas (BL150T) appeared to be quite short and to mostly contain sequences belonging to the Hgfr/Met gene (but not the Hgf gene). This is consistent with a selection acting on the Hgfr/Met gene itself, although it cannot be ruled out that other genes are coampli®ed with Hgfr/Met also in this tumor. Secondly, the amplification of Hgfr/Met has a functional consequence in the overexpression of HGF receptor mRNA and an overproduction of the HGF receptor protein. Thirdly, the tyrosine phosphorylation assay showed that the HGF receptor molecules produced were functional. Fourthly, it would be expected that activation of Hgfr/ Met in tissues of mesenchymal origin might provide a selective growth advantage, since these tissues are known to produce HGF (Matsumoto and .
Unlike the case with the HGF receptor, there was little evidence that production of HGF provided the tumor cells with an advantage for growth and survival. Despite the fact that many cells in normal connective tissue produce the growth factor HGF (Matsumoto and Nakamura, 1996), we found that only some of the sarcomas produced moderate to high levels of HGF. Moreover, we found little correlation between Hgf gene ampli®cation and HGF expression as re¯ected by the levels of HGF mRNA and HGF immunoreactivity in the culture medium. Interestingly, those sarcomas that overexpressed the HGF receptor protein usually displayed a very low level of HGF mRNA, except in the two cases (LB32T and LB131T) where the Hgfr/ Met and HgF genes were coampli®ed. These two sarcomas displayed moderate HGF mRNA levels, but the levels of immunoreactive HGF in the culture medium were unmeasurable. This suggests that the HGF mRNA was either not translated or HGF not released or possibly that HGF was produced but completely bound to the extracellular matrix . Instead, there were measurable levels of HGF in some tumors without HGF receptor expression. In conclusion, there was little evidence for a selective pressure promoting HGF expression and thereby the prerequisites for an autocrine loop in the sarcomas. The tyrosine phosphorylation of the HGF receptor in the tumor cell cultures could be accounted for by a content of HGF or HGF-like peptides in the fetal calf serum that was part of the culture medium. However, we cannot exclude activating mutations in the HGF receptor in the DMBA-induced sarcomas (Maggiora et al., 1997) .
At the present stage we can only speculate about the signi®cance of the Hgfr/Met ampli®cation in these sarcomas. Since mesenchymal cells often produce HGF, one possibility close at hand is that overexpression of Hgfr/Met leads to an autocrine loop of growth stimulation in these cells. As discussed above, the low correlation between expression of HGF and HGF receptor expression, seems to speak against this interpretation. Since HGF is known to be a motogen (originally it was designated`scatter factor'; Matsumoto and Nakamura, 1996) overexpression of the HGF receptor might make the cell more invasive into a surrounding tissue where many cells produce HGF. Several reports have implicated HGF receptor signaling in invasiveness and metastasis (Comoglio and Boccaccio, 1996; Galeazzi et al., 1997; Iwazawa et al., 1996; Jeers et al., 1996) .
To our knowledge this is the ®rst report of Hgfr/Met ampli®cation in experimental tumors. However, there are a few reports of MET gene ampli®cation in human tumors. Thus, Houldsworth et al. (1990) reported of moderate ampli®cation of MET in two out of 28 gastric/esophageal adenocarcinomas, and Kuniyasu et al. (1992) found MET ampli®cation in 15 out of 64 gastric carcinomas. In the latter investigation there was a tendency of correlation between MET ampli®cation and more advanced malignancy. In human glioma, ampli®cation has been reported in six out of 40 tumors (Fischer et al., 1995) .
Overexpression of the HGF receptor has been reported in a number of human malignancies including ovarian and colorectal cancers (Di Renzo et al., 1994) . In addition, the MET gene may become ampli®ed in metastases, suggesting a role for the HGF receptor in tumor progression (Comoglio and Boccaccio, 1996) . HGF receptors are normally expressed in epithelial cells, from which cancers emerge (Rubin et al., 1993) . However, HGF receptor expression, but not MET gene ampli®cation, has been reported from a few human sarcomas, tumors originating from mesodermal tissue that does not normally express these receptors Naka et al., 1997; Rong et al., 1994; Scotlandi et al., 1996) . We have tested a series of 45 human musculoskeletal tumors for expression and/or ampli®cation of the MET oncogene (Wallenius et al., in preparation) . The series contained both malignant and benign tumors, and we detected MET protein expression at various levels in more than 60% of the tumors, but there was no ampli®cation of the MET gene in any of them.
In conclusion, we have established that ampli®cation and overexpression of the Hgfr/Met oncogene is a frequent event in DMBA-induced sarcomagenesis in rats. Overexpression (but not ampli®cation) of the MET gene has been found in certain human musculoskeletal tumors. Our ®ndings may be the foundation for an animal model to evaluate the importance of HGF receptor overexpression in sarcoma development.
Materials and methods
Animals and tumor induction
Young rats from the strains LE/Mol and BN/Han were obtained from M&B A/S (Denmark). Mating cages were set up with a single male from one strain and three females from the other, generating F1 progeny. Animals with a BN mother and an LE father were designated BL, the reciprocal F1 animals were designated LB. At about 3 weeks of age (average 22.6 days, range 20 ± 25 days) 34 F1 animals (22 males and 12 females) were injected subcutaneously in their right thigh with 1 mg (18 animals) or 2 mg (16 animals) of DMBA dissolved in tricaprylin. The animals were checked daily for tumors. During the observation time of 220 days, 21 of the animals (15 males, 6 females) developed tumors. Among the tumors 11 were from animals that had received 1 mg of DMBA and 10 from those that had received 2 mg. The average latency period was about the same for both types, 167 days (range 80 ± 211) for the former and 145 days (range 113 ± 190) for the latter, total average 157 days. Likewise, there was no signi®cant dierence in latency period or tumor incidence between males and females nor between LB and BL animals.
When the tumors had reached the size of a pea, the animals were sacri®ced and normal and tumor tissue material was secured for molecular analysis. Cell cultures were successfully established from 17 of the 21 tumors. In a previous study we have shown that the malignancies obtained by this methodology are ®brosarcomas of various degrees of dierentiation .
Cytogenetic analysis, CGH and FISH analysis
Chromosome preparations were made from all 17 cell cultures and they were subjected to cytogenetic analysis using G-banding (Islam and Levan, 1987) . From each line 10 ± 20 cells were karyotyped. For FISH analysis, metaphase chromosomes were prepared after adding 0.2 mg/ml of 5'-bromo-2'-deoxyuridine (BrdU) to the culture medium for 17 h. The cells were washed three times with culture medium in order to remove the BrdU, and were then cultured for 6 h in DMEM supplemented with 0.05 mg/ml thymidine at 378C. During the ®nal 30 min the cells were treated with 0.05 mg/ml colcemid. The cells were harvested by mitotic shake-o and resuspended in 0.075 M KCl at room temperature for 10 min. Fixation was carried out as described previously (Islam and Levan, 1987) . Slides that had been stored in 70% ethanol at 7208C for no more than 2 weeks were incubated in 26SSC for 30 ± 60 min at 378C prior to use in FISH.
One tumor (LB32T) was analysed with the CGH-method (du Manoir et al., 1993; Kallioniemi et al., 1994) . Total genomic reference DNA (1 mg, from normal rat liver) and test DNA (1 mg, from LB32T cultured cells) was labeled by nick-translation with digoxigenin-11-dUTP and biotin-16-dUTP, respectively, using a commercial kit (Life Technologies Inc., Gaithersburg, MD, USA). The reaction was interrupted at 60 and 90 min by placing the reaction tubes on ice, and the probe fragment lengths were monitored by agarose gel electrophoresis. As the incubation was continued, 0.5 ml of DNA polymerase I (Promega, Madison, WI, USA) was added. When the probe fragment sizes ranged from 200 ± 1500 kb, the reaction was stopped by adding 20 mM Na 2 EDTA (pH 8.0). Equal amounts (400 ng) of labeled reference and test DNA were mixed with 50 mg unlabeled rat (C o t1 DNA which was included in order to suppress probe hybridization to repetitive sequences. The C o t1 DNA had been prepared as described by Nisson et al. (1992) . The probe DNA mixture was then ethanol precipitated and dissolved in hybridization buer (50% formamide, 26SSC, 10% dextran sulfate). After denaturation, the highly repetitive sequences in the probe mixture DNA were allowed to bind to the C o t1 DNA (30 min at 378C) before it was applied to rat ®broblast metaphase chromosome slides (previously denatured at 738C for 4 min in 70% formamide, 26SSC). Hybridization was allowed to proceed in a moist chamber for 70 h at 378C. Subsequently, the slides were washed for 15 min at 458C in 55% formamide, 26SSC, and then in 26SSC (pH 7.0) at 438C for 9 min, followed by 10 min in a blocking buer (3% BSA, 46SSC). The labeled probe molecules were detected with FITC-avidin and rhodamine antidigoxigenin (Oncor, Inc., Gaithersburg, MD, USA) and the slides were washed three times in PBS and 0.1% Nonidet NP-40. Finally, chromosome spreads were counterstained with 4,6-diamino-2-phenylindole (DAPI; 0.5 mg/ml) in an antifade solution (Vectashield 1 , Vector Laboratories, Inc., Burlingame, CA, USA). The images were captured using the LEICA DM RXA in combination with the Q-FISH software for microphotography and Q-CGH hardware package.
For the FISH analysis to determine the cellular sublocalization of Hgfr/Met and Hgf a full length 4.1 kb rat Hgfr/Met cDNA and a genomic rat Hgf probe were used (Wallenius et al., 1997) . The DNA was labeled with digoxigenin-11-dUTP (Boehringer Mannheim, Germany) by nick translation as above. Appropriate length (50 to 500 bp) of the nick translated fragments was ensured by checking the nick translation products on a 1% agarose gel. Hybridization and image analysis was performed as described above.
Molecular analysis
High molecular weight DNA was prepared from the cells according to standard procedures using the 341 Nucleic Acid Puri®cation System Genepur 1 (Perkin-Elmer, Applied Biosystems, Foster City, CA, USA) and a modi®cation of the protocols provided by the manufacturer. DNA was successfully extracted from 19 solid tumors and from the cell cultures derived from 17 of them. In addition DNA was extracted from normal liver tissue from all animals with tumor. For Southern blotting 10 mg of genomic DNA was restricted with EcoRI and loaded on agarose gels. After electrophoresis the DNA was transferred to membranes and probed with radioactively labeled probes (Southern, 1975) . Cytoplasmic RNA was isolated from the 17 cell cultures with the RNeasy 1 Mini Kit (Qiagen Inc., Valencia, CA, USA) and size-fractionated on 1% agarose-formaldehyde gels, according to Maniatis et al. (1982) . The RNA was transferred to nylon ®lters (Hybond-N + , Nycomed Amersham plc, Buckinghamshire, UK) in 106SSC. Conditions for prehybridization were 3 h in hybridization buer (56SSC, 10 mM NaPO 4 , 106Denhard, 0.3 mg/ml salmon sperm DNA, 2% SDS) at 558C and then the hybridization was carried out for 18 h in hybridization buer at 558C. Finally, the ®lters were washed for 4615 min in 16SSC, 0.1% SDS at 558C. Southern and Northern hybridizations with these ®lters were performed with probes that had been radioactively labeled by the random priming method. For Hgf and Hgfr/Met the same probes were used as for FISH. The Myc probe was the human pHSR-1 clone (ATCC, Rockville, MD, USA).
The relative level of Hgfr/Met ampli®cation in the dierent tumors was estimated from the Southern photographic plates. They were scanned by a PhosphorImager 1 scanner (Molecular Dynamics, Sunnyvale, CA, USA). Dierences in loading of the lanes was compensated for by comparing to the Myc hybridization to the same ®lter. The approximate level of ampli®cation was calculated by comparing the ampli®ed samples to the average level in the control lanes containing normal rat DNA.
Western blotting of the rat HGF receptor
For Western blotting, cells were washed three times in 0.01 M PBS (pH 7.45) before harvest and were then scraped o with Costar disposable cell scrapers in 3 ml of 0.01 M PBS. The cells were pelleted by centrifugation and homogenized by sonication for 3615 s in a homogenization buer containing 10 mM K 2 HPO 4 , 10 mM KH 2 PO 4 , 10 mM EDTA and 6.0 mg/ ml CHAPS (3-{(3-Cholamidopropyl) dimetyl ammonio}-1-propanesulfonate) and one tablet of Complete TM (Protease Inhibitor cocktail tablets, Boehringer Mannheim, Germany) per 25 ml of buer. After sonication the cells were centrifuged to pellet any remaining cell debris. The supernatants were collected and the protein concentrations were measured with a Gene Quant II spectrophotometer (Amersham Pharmacia Biotech (Biochrom) Ltd, Cambridge, UK). Sample buer (Novex, San Diego, CA, USA) and 50 mM DTT (dithiotreitol) were added. 30 mg of protein was loaded per lane on NuPage (Novex) 10% Bis-Tris gels and run at 195 V for about 1.5 h. Proteins were then transferred to a PVDF (polyvinylidene di¯uoride) membrane (Novex) by electroblotting. The membranes were blocked overnight by incubation in 10% dry milk in TBS buer (6.056 g/l Tris-OH, 8.0 g/l NaCl and 0.1% Tween 20, pH 7.6). Blots were probed with the rabbit polyclonal anti-mouse Met antibody SP260 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then with an anti-rabbit horseradish peroxidase-linked F(ab')2 fragment (Amersham Life Science, Buckinghamshire, UK), revealed by Enhanced Chemiluminescence (ECL; Amersham). For determination of tyrosine phosphorylation the membranes were stripped at 708C for 45 min in a stripping buer containing 62.5 mM Tris, 2% SDS and 100 mM b-mercaptoethanol. The stripped membranes were then revealed by ECL again to make sure that no secondary antibody was left after the stripping. Subsequently, the membranes were reprobed with the mouse anti-phosphotyrosine IgG (PY 20; Santa Cruz Biotechnology) and then with an anti-mouse horseradish peroxidase-linked F(ab')2 fragment (Amersham), and then revealed by ECL.
Measurement of immunoreactive rat HGF
Media from the cell cultures was aspirated, spun at 3300 g for 20 min at 48C. The supernatants were collected and frozen at 7708C. For the measurement of immunoreactive HGF, a rat speci®c HGF ELISA was used (Institute of Immunology, Tokyo, Japan). In brief, 50 mL of sample medium, in duplicate, was dispensed in a 96 well plate, precoated with a monoclonal anti-human HGF antibody, as described (Yamada et al., 1995) . Rat HGF standard solution was provided by the manufacturer for a standard curve. The plates were incubated overnight at room temperature and then washed and incubated with an anti-rat HGF rabbit polyclonal antibody. Peroxidase labeled anti-rabbit goat immunoglobulin and a substrate was added to give a color reaction. The absorbance was measured with an ELISA spectrophotometer at 490 nm.
